Introduction {#s1}
============

Alzheimer\'s disease (AD) is the most common form of dementia among people over 65 years of age [@pone.0073129-Vina1]. AD is predicted to affect 1 in 85 people globally by 2050 [@pone.0073129-Vina1]. As an incurable degenerative disease, AD gets worse gradually and eventually leads to death. The features of AD development consist of loss of cognitive functions such as thinking, remembering, and reasoning, and ultimately leading to death. The averaged life expectancy after AD diagnosis is seven years [@pone.0073129-Molsa1]. Although hundreds of clinical trials have been conducted to find ways to treat the disease, none has claimed its effect of stopping or reversing the progressive symptoms. Because AD patients rely on others for assistance, it has imposed great economic costs on society [@pone.0073129-BoninGuillaume1], [@pone.0073129-Meek1].

The cause for most AD cases is still largely unknown, although attempts have been made to explain AD by using the hypotheses based on acetylcholine [@pone.0073129-Francis1], amyloid [@pone.0073129-Hardy1], [@pone.0073129-Mudher1], tau [@pone.0073129-Mudher1] and etc. In the present study, we performed meta-analyses for the variants on 6 protein encoding genes, including choline O-acetyltransferase (CHAT), catechol-O-methyltransferase (COMT), alpha-2-macroglobulin (A2M), 5-hydroxytryptamine receptor 6 (HTR6), ATP-binding cassette, sub-family A, member 2 (ABCA2), lipoprotein lipase (LPL). CHAT is an important enzyme catalyzing the biosynthesis of the neurotransmitter acetylcholine [@pone.0073129-Mubumbila1]. Altered protein levels of CHAT in neurons are shown to affect the symptoms of AD containing mild cognitive impairment [@pone.0073129-Kooi1], [@pone.0073129-MengelFrom1]. As one of the serotonin receptors, HTR6 plays a pivotal role in cognitive and memory processes [@pone.0073129-Orlacchio1] that are gradually damaged along with the AD progression. Involved in dopamine system, COMT is an important enzyme catalyzing the transfer of a methyl group from S-adenosylmethionine to catecholamines in the synapse [@pone.0073129-Guldberg1]. *COMT* gene variant is associated with the volumes of ventral tegmental area where the gray matter correlates with cognitive and behavioral deficits in AD patients [@pone.0073129-Gennatas1]. *A2M* encodes a protease inhibitor and cytokine transporter [@pone.0073129-Blacker1], [@pone.0073129-Hughes1]. A2M is important for the clearance and degradation of beta-amyloid [@pone.0073129-Narita1], [@pone.0073129-Herring1] which may lead to the pathogenesis of AD through the induction of tau phosphorylation [@pone.0073129-Jin1]--[@pone.0073129-Lambert1]. *ABCA2* was cholesterol-responsive gene encoded a member of the superfamily of ATP-binding cassette (ABC) transporters [@pone.0073129-Kaminski1]. Over-expression of *ABCA2* causes increased protein levels of amyloid beta precursor protein (APP) and beta-amyloid, both of which are important determinants of AD [@pone.0073129-Chen1]. As a key enzyme to transfer fatty acids from triacylglyceride-rich lipoproteins, LPL is especially important in the process of cholesterol transport in neurons [@pone.0073129-Nunez1]. AD might be related to LPL protein that is one of component of amyloid plaques [@pone.0073129-BenZeev1].

Associations between 8 single-nucleotide polymorphisms (SNPs) of the above 6 genes and AD have been reported in different ethnic groups [@pone.0073129-Orlacchio1], [@pone.0073129-Lee1]--[@pone.0073129-Zill1]. The results of these case-control studies for the above 8 genetic variants with AD differ across different groups. In the present study, we aimed to evaluate the combined contribution of the SNPs in these genes to AD susceptibility in different populations using a meta-analysis approach.

Materials and Methods {#s2}
=====================

Literature search and study selection {#s2a}
-------------------------------------

Literatures were searched through the online databases from 1999 to 2012 using the following key words: "alzheimer\'s disease, association, SNP or polymorphism or variant or variation or mutation". The involved databases include PubMed, Chinese National Knowledge infrastructure (CNKI), Embase, SpringerLink, and ScienceDirect. Reference lists in the harvested literatures were explored for additional case-control studies. The criteria for the selection of literatures in the meta-analyses were as followed: (1) the study was case-control association study; (2) allele or genotype information is available; (3) the involved genetic variants have not been studied in previous meta-analysis. The retrieved information consisted of the first author, the year of publication, the number of participants with the different allele (patients and healthy controls), and the odds ratios (ORs) values with 95% confidence intervals (CIs). In total, 33 publications addressing 8 polymorphisms were included in the current meta-analyses.

Statistical Analysis {#s2b}
--------------------

The meta-analyses were done using the Review Manager 5.0 software [@pone.0073129-Estrela1]. Total ORs with 95% CIs were estimated to evaluate the strength of the association between polymorphisms and AD risk. Heterogeneity was tested by the Cochran\'s Q statistic and I^2^ test [@pone.0073129-Coory1]. A I^2^\<50% denoted a non-signficant heterogeneity among the involved studies in the meta-analysis and fixed-effect model was used in the meta-analyses. The funnel plot was used to evaluate the publication bias in the meta-analysis. A two-sided P value \<0.05 in the Z-test was treated as significant.

Results {#s3}
=======

As shown in [Figure 1](#pone-0073129-g001){ref-type="fig"}, our search for the case-control studies of AD retrieved 3,351 articles from PubMed, Embase, Web of Science, CNKI and Wanfang from 2000 to 2012. After removing the duplicated publications, we harvested 3270 articles. Among them, 1417 studies were discarded for their involvement in the previous meta-analyses. For the rest 476 studies, we filtered out a total of 428 articles because they failed to accumulate at least three independent genotypic datasets for the same genetic variants. At last, there were 33 case-control studies with 8 polymorphisms for the current meta-analyses ([Figure 1](#pone-0073129-g001){ref-type="fig"}).

![Flow diagram of the 8 meta-analyses.](pone.0073129.g001){#pone-0073129-g001}

There was no evidence of statistical heterogeneity for all the SNPs in our meta-analysis. Minimal heterogeneity was observed for *A2M* 5bp-del (I^2^ = 4%, [Figure 2](#pone-0073129-g002){ref-type="fig"}), *CHAT* 1882G \>A (I^2^ = 12%, [Figure 3](#pone-0073129-g003){ref-type="fig"}), *CHAT* 2384G \>A (I^2^ = 0%, [Figure 3](#pone-0073129-g003){ref-type="fig"}), *COMT* Val158Met (I^2^ = 0%, [Figure 3](#pone-0073129-g003){ref-type="fig"}), *HTR6* 267C \>T (I^2^ = 0%, [Figure 3](#pone-0073129-g003){ref-type="fig"}) and *LPL* Ser447Ter polymorphism (I^2^ = 11%, [Figure 3](#pone-0073129-g003){ref-type="fig"}). There was moderate heterogeneity for *A2M* V1000I (I^2^ = 32%, [Figure 2](#pone-0073129-g002){ref-type="fig"}) and *ABCA2* rs908832 polymorphism (I^2^ = 49%, [Figure 2](#pone-0073129-g002){ref-type="fig"}). As shown in the funnel plot, no obvious publication bias was observed for the 8 meta-analyses ([Figure 4](#pone-0073129-g004){ref-type="fig"}). The details were presented in the [Tables 1](#pone-0073129-t001){ref-type="table"} and [2](#pone-0073129-t002){ref-type="table"}.

![Forest plots for the relationship between SNPs (5bp I/D, V1001I, rs908832), and AD in the meta-analyses.](pone.0073129.g002){#pone-0073129-g002}

![Forest plots for the relationship between SNPs (1882G \>A, 2384G \>A, Val158Met, 267C \>T, rs2233678, rs2233679, Ser447Ter) and AD in the meta-analyses.](pone.0073129.g003){#pone-0073129-g003}

![Funnel plots for the relationship between 8 SNPs and AD in the meta-analyses.](pone.0073129.g004){#pone-0073129-g004}
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###### The characteristics of the enrolled SNPs (5bp I/D, V1001I, and rs908832).

![](pone.0073129.t001){#pone-0073129-t001-1}

  Gene         SNP      Year      Author       Ethnic group   No. case/control   Genotype (case/control)   Allele (case/control)                       
  --------- ---------- ------ --------------- -------------- ------------------ ------------------------- ----------------------- -------- ----------- ---------
  *A2M*       5bpI/D                                                                       I/I                      I/D             D/D         I          D
                        2000     Beghi, M         German          102/191                75/139                    27/47            0/5      177/325     27/57
                        2004     Camelo, D       Colombia          51/13                  39/11                    11/2             1/0       89/24      13/2
                        2004      Chen. D        Chinese          166/215                150/175                   8/20             8/20     308/370     24/60
                        2003    Clarmon, J       Spanish           112/91                 77/65                    33/25            2/1      187/155     37/27
                        2001      Jhoo, J         Korean          100/203                89/192                    10/11            1/0      188/395     12/11
                        2001     Ki, C, S         Korean           88/50                  81/45                     6/5             1/0      168/95       8/5
                        2001     Prince, J       Swedish          200/183                139/137                   56/40            5/6      334/314     66/52
                        2002     Zappia, M       Italian          132/184                95/105                    32/72            5/7      222/282     42/86
                        2000      Zill, P         German           89/118                 65/78                    22/39            2/1      152/195     26/41
              V1000I                                                                       AA                       AG               GG         A          G
                        2010     Bruno, E        Italian          125/310                57/174                   58/111           10/25     172/459    78/161
                        2004      Chen, D        Chinese          158/195                127/168                   29/26            2/1      283/362     33/28
                        2003    Clarmon, J       Spanish           112/89                 45/42                    56/36           11/11     146/83      78/58
                        2006    Depbylu, C        German          271/280                 24/45                   127/151          120/84    175/241    367/319
                        2006    Mariani, E       Italian          100/136                 49/70                    41/49           10/17     139/189     61/83
                        2003   Styczynska, M      Polish          100/100                 49/40                    37/41           14/19     135/121     65/79
                        2002     Zappia, M       Italian          132/184                 61/98                    48/77            23/9     119/163     94/95
                        2004     Zappia, M       Italian          148/158                 65/85                    58/65            25/8     188/235    108/81
                        2000      Zill, P         German           89/98                  44/32                    37/56            8/10     125/120     53/76
  *ABCA2*    rs908832                                                CC                    CT                       TT               C          T      
                        2005      Mace, S         French          440/519                376/484                   63/35            1/0     815/1003     65/35
                        2009    Minster, R       American        1228/2012              1160/1920                  67/90            1/2     2387/3930    69/94
                        2006    Wollmer, M        Swiss           122/179                113/177                    9/2             0/0      235/356      9/2
                                                  Greek            269/97                253/89                    15/8             1/0      521/186     17/8
                                                 Japanese         175/121                175/121                    0/0             0/0      350/242      0/0

a:N.A. denotes not available.

10.1371/journal.pone.0073129.t002

###### The characteristics of the enrolled SNPs (1882G \>A, 2384G \>A, Val158Met, 267C \>T, and Ser447Ter)^a^.

![](pone.0073129.t002){#pone-0073129-t002-2}

  Gene         SNP      Year      Author         Ethnic group      No. case/control   Genotype (case/control)   Allele (case/control)                        
  -------- ----------- ------ --------------- ------------------- ------------------ ------------------------- ----------------------- --------- ----------- ---------
  *CHAT*    1882G \>A                                                                           GG                       GA               AA          G          A
                        2011   Grunblatt, E         Italian             37/79                  24/51                    7/26              6/2      55/128      19/32
                        2003     Harold, D          British             68/85                  34/49                    25/33             9/3      93/131      43/73
                        2006     Ozturk, A         American            1001/705               563/369                  376/292           62/44    1502/1030   500/380
            2384G \>A                                                                           GG                       GA               AA          G          A
                        2006     Ahu Jo, S          Korean             316/201                211/192                   99/7              6/2      521/454    111/74
                        2003     Harold, D          British            131/118                 69/65                    51/47            11/6      189/177     73/59
                        2012     Lee, J. J          Korean             736/1386              505/1023                  205/342           26/21    1215/2388   257/384
                                                                                                                                                             
  *COMT*    Val158Met                                                     AA                    AG                       GG                A          G      
                        2006   Forero, D. A        Colombian            99/161                 41/53                    43/90            15/18     125/196    73/126
                        2012     Lanni, C           Italian            276/248                 61/57                   141/131           74/60     259/248    293/248
                        2009   Martmez, M. F        Spanish            345/253                 74/67                   176/125           95/61     324/259    366/247
                        2011    Thornton, V         British            349/340                99/105                   167/151           83/84     365/361    333/319
  *HTR6*    267C \>T                                                                            CC                       CT               TT          C          T
                        2003    Alvarez, M          Basque             173/102                149/81                    23/18             1/3      321/180     25/24
                        2004      Kan, R            Chinese            105/130                70/101                    35/25             0/4      175/227     35/33
                        2002   Orlacchio, A         Italian            127/100                 92/76                    32/19             3/5      216/171     38/29
                        2001     Thome, J           German              69/156                50/107                    17/47             2/2      117/261     21/51
  *LPL*     Ser447Ter                                                                         Ser/Ser                  Ser/Ter          Ter/Ter      Ser        Ter
                        2000      Baum, L          American             290/25                  N.A                      N.A              N.A      522/43      58/7
                                                   Canadian             136/70                  N.A                      N.A              N.A      250/121     22/19
                        1999      Baum, L      European-American       119/315                  N.A                      N.A              N.A      229/568     9/62
                        2002     Fidani, L         Caucasian           459/554                368/444                  85/104             6/6      821/992    97/116
                        2002     Matthew D         American             108/79                  N.A                      N.A              N.A      194/140     22/18

a: N.A. denotes not available.

Meta-analysis of A2M V1000I polymorphism involved 9 studies among 1235 cases and 1550 controls. As shown in [Figure 2](#pone-0073129-g002){ref-type="fig"}, V1000I was risk factors to AD onsets (OR = 1.26, 95% CI = 1.07--1.49, P = 0.007, [Figure 2](#pone-0073129-g002){ref-type="fig"}). A strong association between rs908832 of ABCA2 gene and AD was observed in the meta-analysis of 5 studies among 2234 cases and 2928 controls (OR = 1.55, 95% CI = 1.12--2.16, P = 0.009, [Figure 2](#pone-0073129-g002){ref-type="fig"}). Moderate association was found between the CHAT 2384G \>A polymorphism and AD in the meta-analysis of 3 studies among 1183 cases and 1705 controls (OR = 1.22, 95% CI = 1.00--1.49, P = 0.05, [Figure 3](#pone-0073129-g003){ref-type="fig"}). As shown in [Figure 3](#pone-0073129-g003){ref-type="fig"}, no association of LPL Ser447Ter polymorphism with AD was found in the meta-analysis of 5 studies among 1112 cases and 1043 controls (OR = 0.8, 95% CI = 0.59--1.09, P = 0.16). However, the subgroup analysis by ethnicity found that LPL Ser447Ter polymorphism in the Northern-American population was associated with the risk of AD (OR = 0.56, 95% CI = 0.35--0.91, P = 0.02, [Figure S1](#pone.0073129.s001){ref-type="supplementary-material"}).

In order to test the robustness of the results in the meta-analyses, we perform a series of subgroup meta-analyses by excluding each study in turn, and the results showed that there was a significant association between the 2 SNPs (A2M V1001I, ABCA2 rs908832) with AD (P\<0.05), except for the exclusion of Depbylu\'s study (A2M V1001I) and the Mace\'s study (ABCA2 rs908832) ([Table S1](#pone.0073129.s003){ref-type="supplementary-material"}). For LPL Ser447Ter, the subgroup meta-analysis by excluding Fidani\'s study found a significant association between LPL Ser447Ter and the risk of AD (Z = 2.33, P = 0.02). Moreover, subgroup meta-analyses by ethnicity were also performed to prevent the bias among different ethnic populations ([Figure S1](#pone.0073129.s001){ref-type="supplementary-material"}). Our subgroup meta-analyses indicated that A2M V1000I was a risk factor of AD in Italian population among 171 cases and 212 controls (OR = 1.37, 95% CI = 1.07--1.75, P = 0.01), and LPL Ser447Ter polymorphism was likely to be a protective factor of AD in Northern-American population (OR = 0.56, 95% CI = 0.35--0.91, P = 0.02, [Figure S2](#pone.0073129.s002){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In the present study, we carried out a systematic overview of case-control association studies for the susceptibility of AD. We screened all the available studies to harvest the eligible SNPs that were involved in at least three independent datasets. In the end, 8 SNPs of 6 AD candidate genes were included in the current meta-analyses. Our results showed significant evidence for 2 AD susceptibility SNPs (*A2M* V1000I polymorphism (OR = 1.26, 95% CI = 1.07--1.49, P = 0.007), *ABCA2* rs908832 polymorphism (OR = 1.55, 95% CI = 1.12--2.16, P = 0.009). We also observed a moderate association of AD for *CHAT* 2384G \>A polymorphism (OR = 1.22, 95% CI = 1.00--1.49, P = 0.05), and an association of AD for *LPL* Ser447Ter polymorphism in the Northern-American population (OR = 0.56, 95% CI = 0.35--0.91, P = 0.02). No significant associations were found between the rest 4 SNPs and AD.

Large ethnic differences were observed for some of SNPs such as V1000I (20.8% in Germans versus 4.6% in Chinese), and Val158Met (12.4% in Colombians versus 34.8% in British). Under a moderate risk of AD (OR = 1.2), power analysis showed that there might be a lack of power for the meta-analyses of the 4 SNPs, including 5bp I/D of *A2M* (59.6%), Ser447Ter (56.6%) of *LPL*, rs908832 of *ABCA2* (31.6%) and 267C \>T of *HTR6* (29.9%). These might partly explain our failure to observe significant results for the meta-analyses of most polymorphisms.

A2M is the one of the key ligands for low density lipoprotein receptor-related protein (LRP) which modulates the critical step for the clearance of A-beta, the major component of beta-amyloid [@pone.0073129-Kang1]. A2M may regulate AD progression through its ability to mediate the degradation of A-beta [@pone.0073129-Mettenburg1]. V1000I polymorphism is located near the C-terminal region of A2M which inhibits the β-sheet formation and fibril-formation activities of beta-amyloid [@pone.0073129-Hughes1]. V1000I polymorphism has been shown to increase beta-amyloid directly [@pone.0073129-Zappia1]. Moreover, our meta-analysis has confirmed that *A2M* V1000I polymorphism is associated with a 26% increase in the risk of AD (P = 0.007), although validation of this finding is warranted among other ethnic populations.

As a member in the Sub-family A, ABCA2 may regulate cholesterol homeostasis and LDLR metabolism in neuronal cells [@pone.0073129-Smith1]--[@pone.0073129-Ricciarelli1]. ABCA2 expression has been shown to increase endogenous expression of amyloid precursor protein (APP) and the production of Aβ fragment that is a key player in AD progression [@pone.0073129-Davis2]. SNP rs908832 is C-T polymorphism in exon 14 of the *ABCA2* gene. Our result showed a significant contribution of *ABCA2* rs908832 polymorphism to the susceptibility of AD (OR = 1.55, 95% CI = 1.12--2.16, P = 0.009). Future research is needed to clarify the mechanistic details of this polymorphism.

As the enzyme responsible for the biosynthesis of acetylcholine [@pone.0073129-Oda1], CHAT protein is a marker of evaluating the function of basal forebrain cholinergic cells [@pone.0073129-GilBea1], the dementia severity in Alzheimer\'s disease [@pone.0073129-Bierer1], [@pone.0073129-DeKosky1] and the density of senile plaques [@pone.0073129-Wilcock1]. By modulating levels of acetylcholine, CHAT influences a wide range of cholinergic-dependent neurophysiological functions including cognitive ability [@pone.0073129-Grunblatt1], [@pone.0073129-Kanju1]. In early stage of AD, reduction in CHAT activity is a more sensitive indicator than the loss of cholinergic neurons in AD brains [@pone.0073129-NunesTavares1]. In the current study, two SNPs of *CHAT* gene were analyzed, but only 1882G \>A was shown a moderate association with AD (OR = 1.22, 95% CI = 1.00--1.49, P = 0.05).

Encoding lipoprotein lipase, LPL functions as an Aβ-binding protein promoting cellular uptake and subsequent degradation of Aβ [@pone.0073129-Nishitsuji1]. Lipoprotein lipase genes such as *APOE-ε* and *LPL,* are known to be involved in AD pathogenesis [@pone.0073129-Xie1] [@pone.0073129-Papassotiropoulos1]. LPL has a neuroprotective effect on AD by participating in the pathophysiological effects of oxidative stress [@pone.0073129-Paradis1]. Our meta-analysis indicates that *LPL* Ser447Ter polymorphism is a protective factor of AD in the Northern-American population (OR = 0.56, 95% CI = 0.35--0.91, P = 0.02) and thus supports this above speculation.

There were several limitations in our meta-analyses. Firstly, for some SNPs such as Ser447Ter of *LPL* gene, the involved samples were only limited in a few populations. The results of our meta-analyses may not stand for all ethnic populations. Future investigations in other populations are needed to clarify the contribution of the SNPs of interest to AD susceptibility. Secondly, we didn\'t probe the interaction of the two positive SNPs (*A2M* V1000I and *ABCA2* rs908832) and two less significant SNPs (*CHAT* 2384G \>A and *LPL* Ser447Ter) with *APOE-ε4* genotype which is the strongest risk factor of AD. Thus, we can\'t exclude the possibility that our findings are dependent on *APOE-ε4* genotype. Thirdly, according to the disease onset age, there are two subtypes of AD, early-onset of AD (EOAD) and late-onset of AD (LOAD). A potential stratification by age may exist in the current meta-analyses, although no significant heterogeneity was found for all the 8 meta-analyses ([Table S2](#pone.0073129.s004){ref-type="supplementary-material"} and [S3](#pone.0073129.s005){ref-type="supplementary-material"}). Among all the studies, we are able to get only three study mentioning the age of onset *A2M* 5bp I/D polymorphism. There are a total 111 EOAD and 235 LOAD cases and 129 controls younger than 65 and 338 controls with age equal to or over 65. The subgroup analysis has shown that *A2M* 5bp I/D polymorphism is not associated with AD in both young ([Figure S2](#pone.0073129.s002){ref-type="supplementary-material"}, OR = 0.78, 95% CI = 0.28--2.16, *P = 0.64*) and old (OR = 1.41, 95% CI = 0.62--3.18, *P = 0.41*) subgroups. As shown in the funnel plot of [Figure S2](#pone.0073129.s002){ref-type="supplementary-material"}, no obvious publication bias is shown for the above two meta-analyses. Fourthly, the incidence of female is higher than male in clinical and over half of the subjects participating in all the studies are female [@pone.0073129-Vina1]. As an important factor of AD, gender should be considered as a stratifying variable for the further study exploring the diversity among the results of different studies. Due to a paucity of gender-related information, we are unable to perform the subgroup meta-analyses by gender. Fifthly, as shown in the [Table S4](#pone.0073129.s006){ref-type="supplementary-material"}, we have performed a thorough scanning for the criteria used to determine AD diagnosis. Among all the studies, only one study by Kan did the subgroup analysis of clinic and pathology. Due to a lack of informative subgroup analysis in the involved studies, we discontinue the subgroup analysis by the diagnosis criteria. Sixthly, as shown in the [Table S5](#pone.0073129.s007){ref-type="supplementary-material"}, there are inconsistencies in the presentation of the score of Mini Mental State Examination (MMSE) for controls. This may lead to the discrepancy in the association studies worldwide. Lastly but not least, we didn\'t include the genomewide association studies into our meta-analyses. There are a total of 33 GWA studies on AD in the GWAS catalog (<http://www.genome.gov/page.cfm?pageid=26525384#searchForm>) and 14 studies in the NCBI dbGap dataset (<http://www.ncbi.nlm.nih.gov/gap/?term=alzheimer>). All the loci in our meta-analyses are not presented among the strongest loci in those GWA studies.

In conclusion, we identified significant associations between 2 SNPs (*A2M* V1000I and *ABCA2* rs908832) and AD. Meta-analysis among 1235 cases and 1550 controls has confirmed that *A2M* V1000I is a risk factor of AD in German, Korean, Chinese, Spanish, Italian and Polish populations. Further, meta-analysis among 2234 cases and 2928 controls has confirmed that rs908832 of *ABCA2* gene is a risk factor of AD in French, American, Swiss, Greek and Japanese populations. In addition, meta-analysis among 222 cases and 259 controls indicates a moderate association of *CHAT* 2384G \>A with AD in British and Korean populations. Another meta-analysis among 1112 cases and 1043 controls indicates that *LPL* Ser447Ter polymorphism is likely to be associated with a reduced risk of AD in the Northern-American population (OR = 0.56, 95% CI = 0.35--0.91, P = 0.02).
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